Clinical Research Directory
Browse clinical research sites, groups, and studies.
Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia
Sponsor: Fundación Santa Fe de Bogota
Summary
Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued. Maintenance therapy, in which patients whose disease is at least stable after induction chemotherapy continue on a less toxic regimen, is increasingly used, most often with fluoropyrimidines (capecitabine, 5-fluorouracil or S-1) and, in selected molecular subgroups, with immunotherapy or targeted therapy. Evidence on the outcomes of these strategies in Latin American patients is scarce. This multicenter retrospective study will review the medical records of adults with metastatic gastric cancer treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia, who received maintenance therapy after achieving at least stable disease with induction chemotherapy. The study will describe the demographic, clinical, pathological and molecular characteristics of these patients and estimate overall survival, progression-free survival, treatment response, toxicity and mortality. The investigators will not assign or modify any treatment.
Official title: Impact of Maintenance Therapy With Fluoropyrimidines, Immunotherapy or Targeted Therapies in Metastatic Gastric Cancer: A Retrospective Multicenter Study in High-Complexity Institutions in Latin America
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2026-01-01
Completion Date
2027-03-01
Last Updated
2026-10-02
Healthy Volunteers
No
Interventions
Fluoropyrimidine Maintenance Therapy
Fluoropyrimidine-based maintenance therapy (capecitabine, 5-fluorouracil or S-1) administered after induction chemotherapy in routine clinical practice. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.
Immune Checkpoint Inhibitor Maintenance
Immune checkpoint inhibitors (such as nivolumab, pembrolizumab or atezolizumab) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.
Targeted Therapy Maintenance
Targeted therapy (such as trastuzumab in HER2-positive disease) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.
Locations (4)
Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Bogotá, Bogota D.C., Colombia
Clínica del Country
Bogotá, Bogota D.C., Colombia
Hospital Universitario Fundación Santa Fe de Bogotá
Bogotá, Bogota D.C., Colombia
Los Cobos Medical Center
Bogotá, Bogota D.C., Colombia